



107 College Road East  
 Princeton, NJ 08540  
 Tel: 609.608.1246  
 jcalvarez@drreddys.com

**VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov**

March 25, 2020

Vermont Attorney General’s Office  
 109 State Street  
 Montpelier, VT 05609

**RE: New Prescription Drug – 30-Day Notice**

Dear Sir or Madam,

Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”) is providing this information in accordance with 18 V.S.A. § 4637(c), which requires that prescription drug manufacturers notify the Office of the Attorney General and to provide certain information following the release of a drug in the commercial market whose Wholesale Acquisition Cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

NDC:	55111-0289-60 55111-0701-60
Product Description:	Naproxen Esomeprazole 375-20mg DR Tab Naproxen Esomeprazole 500-20mg DR Tab
Date of Introduction to Market:	02/26/2020 (for both SKUs)
WAC:	Naproxen Esomeprazole 375-20mg DR Tab 60ct \$1613.43 Naproxen Esomeprazole 500-20mg DR Tab 60ct \$1613.43
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	This is a generic equivalent of an existing innovator product. Dr. Reddy's may reach out to prescribers and pharmacists to promote awareness of availability of generic product. For this purpose, we may provide them with product sell sheets which include product name, product description, available pack information, and order entry details in the form of mailers or emails.
The estimated volume of patients that may be prescribed the drug	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Naproxen Esomeprazole product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredients.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	No
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	No

The date and price of acquisition if the drug was not developed by the manufacturer	N/A
---	-----

Please do not hesitate to contact us if you have any questions.

Regards,



Juan Alvarez  
Government Contracts & Pricing  
Dr. Reddy's Laboratories, Inc.